Precede Biosciences
Precede Biosciences is a Boston-based liquid biopsy company that profiles circulating chromatin and DNA methylome from 1mL of plasma to infer gene expression, pathway activity, and cell states, serving biopharmaceutical developers of next-generation precision cancer therapies and academic researchers through its Precede Bio Insight RUO platform and Precede Bio Dx clinical-trial product.
- Company typePrivate
- Founded2023
- HeadquartersBoston, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Precede Biosciences does
Precede Biosciences is a privately held Boston-based biotechnology company that has built a first-in-class liquid biopsy platform for profiling disease-defining transcriptional biology from a 1mL plasma sample. The platform profiles circulating chromatin and the DNA methylome across approximately 20,000 gene promoters, 1 million gene enhancers, and 50,000 CpG islands, then applies proprietary machine-learning classifiers to infer gene expression, pathway activity, and cell states genome-wide. The company was co-founded as a spinout from Dana-Farber Cancer Institute through 5AM Ventures' 4:59 Initiative, with scientific co-founders Sylvan Baca, Toni Choueiri, and Matthew Freedman.
The company delivers this capability through two products: Precede Bio Insight, a Research Use Only (RUO) product offering genome-wide quantitative profiling for biopharmaceutical R&D and academic research, and Precede Bio Dx, which adapts the same platform for clinical-trial patient selection based on target expression, pathway activity, and cell states. Validated use cases include HER2 (AUC 0.97), ER (AUC 0.90), MET (AUC 0.97 in osimertinib-progressing NSCLC), and PSMA classifiers correlated with PSMA-PET imaging, across 15 cancers. The company serves biopharmaceutical developers of next-generation precision medicines (ADCs, radioligands, immune-conjugates, next-generation endocrine therapies), academic and translational research institutions (Dana-Farber, Fred Hutchinson, Emory, Duke, OHSU), and, prospectively, healthcare providers through a future clinical Dx channel.
The business model is a direct, enterprise-field-sales motion into biopharma R&D, structured as research collaborations and RUO service agreements, with a conference-led demand-generation strategy (AACR, ASCO, ESMO, SABCS, ECTRIMS). The company is venture-backed, having raised approximately $83.5M to date ($57M Series A in October 2023 and $63.5M Series B plus a $20M credit facility in January 2026) at a $140.5M post-money valuation, from a syndicate that mixes dedicated life-sciences investors (5AM Ventures, Lilly Asia Ventures, Illumina Ventures, Osage University Partners) with strategic biopharma and channel investors (Bristol Myers Squibb, Labcorp Venture Fund, UPMC Enterprises, Mirae Asset Capital Life Science, Alexandria Venture Investments, Qatar Investment Authority, Binney Street Capital of Dana-Farber). Pricing is not publicly disclosed, and there is no reseller or distributor network.
Precede Biosciences firmographics
Firmographics- Name
- Precede Biosciences
- Legal name
- Precede Biosciences, Inc.
- Website
- https://precede.bio
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Precede Biosciences is a Boston-based liquid biopsy company that profiles circulating chromatin and DNA methylome from 1mL of plasma to infer gene expression, pathway activity, and cell states, serving biopharmaceutical developers of next-generation precision cancer therapies and academic researchers through its Precede Bio Insight RUO platform and Precede Bio Dx clinical-trial product.
- Ownership category
- akta.pro rank
Precede Biosciences industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)
Keywords
Where Precede Biosciences is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Precede Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Platform Services for Drug Developers (Research Use Only): Precede Bio's platform is made available to biopharmaceutical drug developers and academic researchers as a Research Use Only (RUO) product. This is the primary revenue-generating model where the company provides genome-wide liquid biopsy profiling services to support drug development, patient selection, and biomarker discovery.
- Clinical Diagnostic Tests: Development of blood-based clinical tests (Precede Bio Insight™ and Precede Bio Dx™) for use in clinical practice to guide precision cancer treatment decisions, replacing or supplementing invasive tissue-based diagnostics.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
Precede Biosciences product offering
Product offeringCore offering
Precede Biosciences operates a first-in-class comprehensive epigenomic liquid biopsy platform that profiles circulating chromatin and the DNA methylome from just 1mL of plasma, delivering genome-wide inference of gene expression, pathway activity, and cell states. The company delivers two commercial products on this platform: Precede Bio Insight™ (a Research Use Only product for biopharma and academic research collaborations) and Precede Bio Dx™ (a clinical trials product enabling non-invasive patient selection based on target expression, pathway activity, and cell states).
Product overview
Precede Biosciences offers a unified liquid biopsy platform with two distinct products: Precede Bio Insight™ for research-use genome-wide functional profiling and Precede Bio Dx™ for clinical trial applications. Both products leverage the same core platform technology that analyzes circulating chromatin and DNA methylome from 1mL of plasma to provide genome-wide transcriptional biology insights, enabling researchers and clinicians to understand disease biology in real time for patient selection, therapeutic development, and treatment decisions.
Differentiator
Problem solved
Functional benefit
Brands
- Precede Bio Insight: First-of-its-kind liquid biopsy product enabling genome-wide inference of gene expression, pathway activity, and cell states from just 1mL of plasma
- Precede Bio Dx
Products and services
- Precede Bio Insight™ A first-of-its-kind genome-wide liquid biopsy product that enables genome-wide inference of gene expression, pathway activity, and cell states from just 1 mL of plasma. Powered by comprehensive epigenomic profiling of cell-free DNA and advanced machine learning, Insight generates quantitative measures of tumor and immune transcriptional biology including target expression, pathway activity, and cell states. Available for R&D collaborations with biopharmaceutical and academic research partners as a Research Use Only (RUO) product.
- Precede Bio Dx™ Clinical trials product that brings Precede's comprehensive epigenomic profiling platform into clinical trial settings, enabling non-invasive patient selection based on target expression, pathway activity, and cell states. Designed to support drug developers in identifying biology associated with response and resistance, identifying novel targets, informing patient selection for clinical trials, and guiding combination and sequencing strategies for precision medicines.
- Precede Liquid Biopsy Platform A first-in-class liquid biopsy platform that profiles circulating chromatin and DNA methylome from just 1mL of plasma. The platform provides genome-wide resolution into ~20K gene promoters, ~1M gene enhancers, and ~50K CpG islands, enabling dynamic analysis of gene and pathway activation in diseased tissues from a simple blood draw. Available as Research Use Only (RUO) to drug developers and academic researchers.
Quantifiable outcome
- HER2 classifier AUC of 0.97 for HER2 3+ vs HER2 0 in metastatic breast cancer patients with detectable ctDNA
- +5 more outcomes
Companies that use Precede Biosciences
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
Precede Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Precede Biosciences partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered major and core.
- AstraZenecamajorASCO 2026 data included studies on MET activation in EGFR-mutated advanced NSCLC patients progressing on osimertinib (AstraZeneca's EGFR inhibitor), demonstrating the platform's ability to inform patient selection and resistance monitoring for targeted therapy combinations.
- Dana-Farber Cancer InstitutecoreDana-Farber Cancer Institute is a co-founder institution and active research collaborator. Co-founders Sylvan Baca, MD, PhD, Toni Choueiri, MD, and Matthew Freedman, MD are faculty members. Multiple joint studies presented at AACR 2026, including characterization of functional ER dependence and neuroendocrine prostate cancer profiling.
- Fred Hutchinson Cancer CentermajorFred Hutchinson Cancer Center collaborated on AACR 2026 studies demonstrating the platform's ability to predict therapeutic response and reveal resistance mechanisms in breast and prostate cancer.
- GenentechmajorGenentech collaborated on AACR 2026 data demonstrating that a liquid biopsy assay of estrogen receptor activity predicts response to giredestrant in ER+/HER2- advanced breast cancer, supporting development of next-generation SERD therapies.
- Emory University School of MedicinemajorEmory University School of Medicine collaborated on AACR 2026 studies including plasma-based comprehensive epigenomic profiling enabling multiplexed prediction of target gene expression and detection of resistance mechanisms in neuroendocrine prostate cancer. Dr. Jacob E. Berchuck led related PSMA studies.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Precede Biosciences competitors and assessment
Company assessmentDirect peers
- Guardant Health: Established liquid biopsy company offering comprehensive genomic profiling (Guardant360) and MRD (Guardant Reveal) tests for oncology. Most directly comparable to Precede in the liquid biopsy precision-oncology category, though Guardant focuses on ctDNA mutation/single-molecule-level detection rather than epigenomic profiling.
- Natera: Molecular diagnostics company with Signatera (tumor-informed MRD) and other oncology blood-based tests. Direct peer in the liquid biopsy / oncology patient-selection space, with established biopharma and clinical channels Precede is targeting.
- Personalis: Genomics-based liquid biopsy player (NeXT Personal liquid biopsy assay) focused on ultrasensitive MRD and tumor profiling for biopharma trial patient selection. Closest peer to Precede by platform category and target customer (biopharma), though Personalis uses genomic rather than epigenomic readouts.
- NeoGenomics: Specialized oncology reference lab offering both tissue and liquid biopsy comprehensive genomic profiling for solid tumor and MRD use cases. Comparable in oncology diagnostic service delivery and biopharma partnership orientation.
Broad incumbents
- Foundation Medicine: Roche-owned leader in comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx) used for oncology patient selection and biopharma trial enrollment. Direct category competitor for cancer liquid biopsy and the platform against which Precede Bio Dx would most likely be benchmarked in clinical trials.
- Exact Sciences: Diversified molecular diagnostics leader with Cologuard and the acquired Thrive/CancerSEEK programs. Competitor in oncology liquid biopsy and biomarker discovery with far larger commercial infrastructure and scale Precede would need to challenge.
- Tempus AI: AI-enabled precision medicine company combining broad genomic profiling with multimodal data and biopharma trial services. Competes for the same biopharma patient-selection and biomarker-discovery budget as Precede Bio Insight.
Emerging players
- Caris Life Sciences: Molecular profiling company offering MI Profile (tissue) and MI Cancer Seek (blood) comprehensive assays across DNA, RNA, and protein for oncology patient selection. Comparable in offering multi-omic / comprehensive profiling from blood, with overlapping biopharma customers.
- Adaptive Biotechnologies: ImmunoSEQ and clonoSEQ diagnostics apply sequencing-based blood profiling to characterize immune and minimal residual disease biology. Adjacent in the blood-based oncology/biomarker profiling category, particularly for immune-cell readouts that complement Precede's chromatin/methylation assays.
Regional players
- Burning Rock Biotech: China-based oncology liquid biopsy and precision diagnostics company with US operations. Comparable in offering comprehensive NGS liquid biopsy for cancer patient selection, primarily a regional rather than US-headquartered competitor.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Precede Biosciences social profiles
Digital presencePrecede Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Precede Biosciences leadership team
Management profileNumber of profiles
Profiles14 records
Precede Biosciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Precede Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Precede Biosciences
What does Precede Biosciences do?
Precede Biosciences operates a first-in-class comprehensive epigenomic liquid biopsy platform that profiles circulating chromatin and the DNA methylome from just 1mL of plasma, delivering genome-wide inference of gene expression, pathway activity, and cell states. The company delivers two commercial products on this platform: Precede Bio Insight™ (a Research Use Only product for biopharma and academic research collaborations) and Precede Bio Dx™ (a clinical trials product enabling non-invasive patient selection based on target expression, pathway activity, and cell states).
Is Precede Biosciences a public or private company?
Precede Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Precede Biosciences founded?
Precede Biosciences was founded in 2023. It employs 51 to 100 people.
Where is Precede Biosciences based?
Precede Biosciences is headquartered in Boston, United States, in the North America region.
How does Precede Biosciences make money?
Two revenue lines are on record. Platform Services for Drug Developers (Research Use Only) is the primary driver. The others are clinical Diagnostic Tests.
Who are Precede Biosciences's main competitors?
Direct peers on record are Guardant Health, Natera, Personalis and NeoGenomics. Broad incumbents are Foundation Medicine, Exact Sciences and Tempus AI. Emerging players are Caris Life Sciences and Adaptive Biotechnologies. Burning Rock Biotech is listed as a regional player.
Does Precede Biosciences have an API?
No public API is recorded for Precede Biosciences.
What industry is Precede Biosciences in?
Precede Biosciences's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing. Its NAICS code is 541714 and its SIC code is 2835.